Two Tris Pharma NDAs filed

Tris Pharma, a privately-owned US specialty firm developing innovative drug delivery technologies, says that the Food and Drug Administration  has accepted its first two New Drug Applications for once-daily  formulations of an un-named cardiovascular drug. If approved, Tris  Pharma's liquid and solid dosages will provide an alternative to the  currently-available immediate release, twice-a-day tablet.

LiquiXR is the liquid dosage form of the company's proprietary OralXR  platform. Only two extended-release liquid pharmaceuticals exist at  present. If the FDA approves Tris' liquid formulation, it will be the  first sustained-release liquid commercialized in more than 25 years and  the first-ever liquid dosage form available in a 24-hour extended  release formulation, the company claims.